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Familial Hypercholesterolemia and Treatments
Elevated serum cholesterol concentrations, defined as greater than 240 mg/dL, affect
more than 25 percent of Americans and can lead to early coronary heart disease (Taylor et al.,
2017). One cause of elevated cholesterol concentrations is a genetic disorder called familial
hypercholesterolemia (FH). FH is dominantly inherited and typically identified by high
concentrations of LDL in blood. FH is the most common genetic cardiovascular disease affecting
approximately 14-34 million people worldwide (Nordestgaard et al., 2013).
FH is a general term used to describe mutated genes that lead to elevated plasma LDL
concentrations. The three major genes known to play a role in plasma LDL regulation and FH
are low density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein
convertase subtilisin/kexin type 9 (PCSK9) (Sturm, 2018). Mutations in any of these three genes
can lead to high plasma LDL, but severity can differ based on the number of dominant alleles
inherited. Heterozygous FH (HeFH) individuals tend to have total cholesterol concentrations
between 310-580 mg/dL and homozygous FH (HoFH) individuals have cholesterol
concentrations between 460-1160 mg/dL. Some may also be double heterozygotes meaning there
are heterozygous mutations in two of the genes causing an intermediate cholesterol concentration
between HeFH and HoFH (Nordestgaard et al., 2013). HeFH affects one in every 200 people and
increases the risk of a coronary event in males by 50% by the age of 50 and 30% by the age of 60
for females. HoFH is predominantly found in the LDLR gene and affects one in every 200,000300,000 people. HoFH leads to greater atherosclerosis and cardiovascular disease than HeFH and
if left untreated, can lead to early death (Sturm, 2018).

As stated previously, a significant component of LDL is cholesterol. Cholesterol is a
major component of cell membranes, precursor of steroid hormones such as cortisol, androgens,
and estrogen, and is converted to bile acids by the liver to aid in digestion and absorption of fats.
Cholesterol is synthesized in cells via a biochemical pathway. Acetyl-CoA is converted to
hydroxymethylglutaryl-CoA (HMG-CoA) and then to mevalonate by HMG-CoA
reductase. Mevalonate is converted to isoprene through a few more reactions and then six
isoprene molecules are condensed to form squalene. From squalene, more than twenty steps
occur to produce cholesterol. The HMG-CoA reductase reaction is the rate limiting step of
cholesterol biosynthesis, and is therefore a major target to treat elevated cholesterol
concentrations. HMG-CoA reductase can be controlled through competitive inhibition, allosteric
effects, and covalent modification such as phosphorylation, but the major regulator for HMGCoA reductase is a feedback mechanism that controls the amount of the enzyme present in cells
(Voet et al., 2016, pp. 706-711).
It is important to maintain adequate concentrations of cholesterol in the body to serve its
essential functions but too much becomes extremely dangerous over time. High concentrations
of LDL can cause lipids to deposit in the walls of blood vessels triggering an inflammatory
response. The endothelial cells of the vessel will help to recruit white blood cells that delve into
the walls of the vessel and take up lipids which causes the formation of foam cells. This damage
to the walls of the vessel causes the formation of plaques which consist of cholesterol and dead
macrophages. Smooth muscle surrounds these plaques and may calcify causing hardening of the
artery. The plaques may become large enough to block the flow of blood through the artery, but
typically the plaque will rupture, or a piece will break off causing a blood clot. This blood clot
may then lead to myocardial infarction or stroke (Voet et al., 2016, pp. 713).

The LDLR gene codes for a receptor protein primarily found in hepatocytes. It is
responsible for the uptake of LDL into cells for the use of cholesterol (Goldstein and Brown,
2009.) As of 2013, there have been more than 1200 mutations identified in the LDLR gene that
affect all the functional domains. LDLR mutations account for about ninety percent of all HeFH
mutations (Nordestgaard et al., 2013).
APOB is another gene involved in the regulation of plasma LDL. B-100 is a large protein
product of this gene that binds to LDL. Arg3500Gln is a mutation that changes the binding
between an arginine and tryptophan residue which lowers the binding affinity to the LDL
receptor, resulting in elevated plasma LDL concentrations (Andersen et al., 2016). This is the
only common mutation in the APOB gene and accounts for about five percent of HeFH
mutations (Nordestgaard et al., 2013).
The final gene associated with FH is PCSK9 which is a 692 amino acid serine protease
that is primarily found in hepatocytes but is also expressed in the intestine, kidneys, and central
nervous system. At the membrane of hepatocytes, PCSK9 associates with LDLR causing the two
proteins to be internalized in a vesicle and transported to the lysosome for degradation (Hess et
al., 2018). This gene has over 20 known mutations which account for about one percent of HeFH
mutations (Nordestgaard et al., 2013). These mutations are gain-of-function which cause a
greater amount of LDL receptors to be degraded than normal. A low number of LDL receptors
results in less LDL being removed from the blood and ultimately elevated plasma LDL
concentrations.
Heart disease has remained the leading cause of death for over twenty years worldwide,
with nearly nine million deaths in 2019 (Pan American Health Organization, 2020). LDL
concentrations are one of the greatest factors contributing to heart disease, yet

hypercholesterolemia remains vastly underdiagnosed. This is the case because high cholesterol
has no symptoms and must be detected through a blood test. Accumulation of lipids in the skin
and tendons called tendon xanthomas may present as a symptom, but this usually only occurs
with more severe hypercholesterolemia (Voet et al., 2016, pp. 713). Although being vastly
underdiagnosed, there have been several significant developments in medications and treatments
to lower plasma LDL concentrations.
Statins were first developed in the 1980’s and are now some of the most common drugs
prescribed in the United States. Some of the statin medications include atorvastatin, rosuvastatin,
and lovastatin. HMG-CoA reductase is the enzyme responsible for converting HMG-CoA to
mevalonate in the pathway of cholesterol synthesis. Statins work by competitive inhibition of
HMG-CoA reductase to reduce cholesterol biosynthesis (Farnier and Davignon, 1998). Statins
have a very small inhibitor constant, K , which indicates they have a great binding affinity for the
I

enzyme and small doses of the medication are needed to be effective. These medications
effectively interfere with enzyme activity because they have bulky hydrophobic regions that
cause conformational changes in HMG-CoA reductase (Voet et al., 2016, pp. 712). Once HMGCoA reductase is blocked, the end products of the mevalonate pathway decrease which causes
activation of transcription factors called sterol regulatory element binding proteins. These
transcription factors upregulate transcription of HMG-CoA reductase gene and LDLR gene.
Upregulation of LDLR causes there to be more receptors present for removing LDL from the
blood and thus lowering plasma LDL concentrations (Clendening et al., 2010).
Ezetimibe is another medication used to treat elevated cholesterol concentrations. It is
typically used in addition to statins when statins alone cannot lower LDL to target
concentrations. Ezetimibe inhibits a transporter in the intestinal lining and hepatocytes called

Niemann-Pick C1-like 1 (NPC1L1). NPC1L1 is responsible for the uptake of cholesterol from
the diet in the intestine and reuptake of cholesterol from bile acids in hepatocytes. Ezetimibe
causes decreased delivery of cholesterol to the liver which results in the upregulation of LDL
receptors further reducing plasma LDL concentrations. Since less cholesterol is absorbed, greater
amounts of cholesterol will be excreted in the stool. Treatment with ezetimibe lowered total
cholesterol by 15 percent, LDL was lowered by 19.8 percent, fecal excretion of cholesterol
increased 66.6 percent, and there was no effect on HDL or triglyceride concentrations (Lin et al.,
2017). Ezetimibe appears to be a successful treatment in addition to statins to lower plasma LDL
concentrations.
The mechanism of ezetimibe is unclear, but the shuttling of NPC1L1 in the cell is
regulated by cholesterol. When cholesterol concentrations are high, NPC1L1 is transported to the
plasma membrane, but when cholesterol concentrations are low, NPC1L1 is internalized to
reduce uptake. It is proposed that NPC1L1 uptake of cholesterol occurs through vesicular
endocytosis which requires microfilaments and clathrin/AP2 complex (Ge et al., 2008). In 2008,
several ideas were proposed for the mechanism of ezetimibe inhibition. Ge et al. proposed that
ezetimibe may competitively inhibit NPC1L1 by binding to its sterol sensing domain where
cholesterol would usually bind. It may also inhibit the conformational change of NPC1L1
induced by cholesterol binding and does not directly compete for the same binding site. Finally,
they proposed ezetimibe may interfere with distribution of cholesterol in the plasma membrane
which limits the binding of cholesterol to NPC1L1 (Ge et al., 2008). More recent studies
provide conflicting ideas on the mechanism of NPC1L1 and ezetimibe action involving vesicular
endocytosis. Xie et al. says that NPC1L1 mediates the transport of cholesterol into enterocytes in
the small intestine of mice through vesicular endocytosis and that ezetimibe blocks this step

(2021). Johnson and Pfeffer say ezetimibe does not alter the rate of NPC1L1 endocytosis in rat
hepatocytes and that NPC1L1 does not require endocytosis for the uptake of cholesterol
(2016). Ezetimibe is an effective drug for lowering plasma LDL concentrations although the
mechanism of this transport protein and inhibitor requires further research.
Bile acid sequestrants are another treatment if statins and ezetimibe are unsuccessful at
lowering LDL concentrations. Cholesterol is converted to bile acids through a process involving
seventeen different enzymes in the liver. Approximately 500 mg of cholesterol is converted to
bile acids each day. Bile acids are transported to the intestine to aid in emulsification and uptake
of fat-soluble vitamins and lipids. About 95% of these bile acids are transported back to the liver
to be reused. Bile acid synthesis is highly regulated so that when there are excess bile acids,
synthesis is decreased, and when there is low supply, synthesis is increased. This regulation is
important to ensure sufficient bile acids are released into the intestines for emulsification to
occur. This tight regulation of bile acid synthesis is exploited as a drug strategy with bile acid
sequestrants to ultimately lower plasma cholesterol concentrations (Russell, 2003).
Cholestyramine, colestipol, and colesevelam are bile acid sequestrants that currently have
FDA approval to manage hypercholesterolemia (Lent-Schochet and Jialal, 2022). They are
nondigestible and positively charged compounds that form a complex with bile acids. This
causes the bile acids to be excreted in the feces rather than resorbed and transported to the
liver. Decrease in return of bile acids to the liver causes the upregulation of bile acid synthesis,
increasing the amount of cholesterol metabolized to form bile acids, and therefore, lowering
plasma cholesterol concentrations. Colesevelam is also approved for glycemic control in type 2
diabetes mellitus patients because it helps to lower plasma glucose concentrations, reduce
urinary glucose excretion, and lower glycosylated hemoglobin A concentration (Staels et al.,
1c

2010). These medications have proven to be another successful option to treat elevated
cholesterol concentrations.
PCSK9 is the protease responsible for degrading LDL receptors and another target to
lower plasma LDL concentrations. Alirocumab and evolocumab received FDA approval in 2015
for high cholesterol treatment when high doses of statins do not sufficiently lower LDL
concentrations (Dayoub et al., 2021). PCSK9 inhibitors work by binding to the catalytic site of
PCSK9 and inhibiting the binding of LDLR, therefore preventing its degradation. By preventing
LDL receptor degradation, more LDL will be removed from the blood. These inhibitors have
been found to reduce plasma LDL concentrations by about 65 percent in healthy individuals and
60-80 percent in those with hypercholesterolemia. This is the mechanism of the two current
PCSK9 inhibitors with FDA approval. Another mechanism to inhibit PCSK9 uses small
interfering RNA molecules that lead to mRNA degradation, and therefore, no translation of
PCSK9. This mechanism underwent Phase 1 of clinical trials but was terminated for unknown
reasons so there are currently no FDA approved PCSK9 inhibitors with this mechanism of action
(Hess et al., 2018).
Although there is promising research on the effects of PCSK9 inhibitors on plasma LDL
concentrations, they are not widely utilized. A study was conducted on 126,419 insured statin
prescribed patients with history of atherosclerotic cardiovascular disease. Less than 1 percent of
these patients were started on PCSK9 inhibitors after FDA approval and by mid-2019, only
approximately 2 percent of the patients were on PCSK9 inhibitors. Clinical trials have
shown PCSK9 inhibitors to be effective in improving cardiovascular risks, but there is still very
low usage. The cost of the inhibitors and access to specialists’ are leading causes of low PCSK9
inhibitor use. Two-thirds of insurers have limited PCSK9 prescribing to certain specialists. High

income individuals are more likely to be prescribed PCSK9 inhibitors due to cost and access to
specialized prescribers, although these drugs have shown great promise in hypercholesterolemia
treatment (Dayoub et al., 2021).
Lastly, another treatment to lower plasma LDL concentrations is lipoprotein apheresis.
This treatment is typically for individuals with homozygous FH and compound heterozygous FH
who have not had success with other treatments. It is much more rigorous than the other
treatments and is reserved for severe cases of hypercholesterolemia. Two types of lipoprotein
apheresis were performed on HoFH children with controlled diets and statin use (Gokay et al.,
2016). Cascade filtration (CF) and double filtration plasmapheresis (DFPP) were used, and their
efficiencies were compared. In CF, two systems for separation were used that ultimately
removed LDL and other components of the blood that have large weights and diameters such as
HDL. In DFPP, two filters were used to extract the LDL from the blood. Both techniques were
effective in reducing plasma LDL concentrations, but there was less HDL reduction in DFPP
than CF treatment. DFPP may be the better option for long term treatment because CF could
cause decreases in large proteins such as immunoglobulins, albumin, and fibrinogen (Gokay et
al., 2016).
Familial hypercholesterolemia is a great threat around the world today as it has no
symptoms. These mutations typically are not lethal until after reproductive age so frequency
may increase in the future and contribute to increased cardiovascular and stroke related
deaths. It is crucial to increase public awareness regarding high cholesterol concentrations and
encourage routine blood work to monitor cholesterol. Although there have been significant
strides to improve recognition and treatment for hypercholesterolemia over the past few decades,
there is still much work to be done. For individuals that are even diagnosed, many of these

treatments come with undesirable side effects, are ineffective, or too expensive. The
underdiagnosis and undertreatment of FH must remain a large focus in research to reduce the
millions of deaths from heart disease and strokes around the world.
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